Pharmacokinetics of saquinavir hard gel/ritonavir (1000/100 mg twice daily) when administered with tenofovir diproxil fumarate in HIV-1-infected subjects.
about
Potencies of human immunodeficiency virus protease inhibitors in vitro against Plasmodium falciparum and in vivo against murine malariaClinical and pharmacokinetic data support once-daily low-dose boosted saquinavir (1,200 milligrams saquinavir with 100 milligrams ritonavir) in treatment-naive or limited protease inhibitor-experienced human immunodeficiency virus-infected patients.Lack of pharmacokinetic drug interaction between tenofovir disoproxil fumarate and nelfinavir mesylatePharmacokinetics of tenofovir disoproxil fumarate and ritonavir-boosted saquinavir mesylate administered alone or in combination at steady stateEffect of a modified saquinavir/ritonavir dosing regimen with lower dose lead-in phase on QTc interval, pharmacokinetics, antiviral activity and safety in treatment-naïve HIV-1-infected patientsPharmacokinetic interaction between TMC114/ritonavir and tenofovir disoproxil fumarate in healthy volunteers.Use of tenofovir disoproxil fumarate and emtricitabine combination in HIV-infected patients.Population pharmacokinetics of ritonavir-boosted saquinavir regimens in HIV-infected individuals.Pharmacokinetic analysis to assess forgiveness of boosted saquinavir regimens for missed or late dosing.Cytochrome P450 3A inhibition by atazanavir and ritonavir, but not demography or drug formulation, influences saquinavir population pharmacokinetics in human immunodeficiency virus type 1-infected adults.
P2860
Q24538763-56CBC2D6-B441-4B51-83FC-E3181BCD295DQ31106166-3FDD7F32-AA25-4C18-8A80-439E1DCFCD2AQ34077060-14694C79-A333-4215-A3C5-39D81F230392Q34510726-6D8466FE-9091-4B1C-86B2-0828B3C8C563Q35175922-2A4BBED4-D8EF-46EA-A95D-AD93BD26878DQ36388067-A9876DBF-689F-4602-9815-419C909C5BCBQ36429743-2DF46D05-2B4D-4259-9B07-D9AC912B6F14Q36683435-2A34D035-4AEA-4090-AB7C-E7570718848DQ36903907-A67C1B79-022B-4C97-9738-BD7F898B0E2EQ37274648-8CD3BE47-D08D-4B7C-BDFF-509C148AC437
P2860
Pharmacokinetics of saquinavir hard gel/ritonavir (1000/100 mg twice daily) when administered with tenofovir diproxil fumarate in HIV-1-infected subjects.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Pharmacokinetics of saquinavir ...... te in HIV-1-infected subjects.
@en
type
label
Pharmacokinetics of saquinavir ...... te in HIV-1-infected subjects.
@en
prefLabel
Pharmacokinetics of saquinavir ...... te in HIV-1-infected subjects.
@en
P2093
P2860
P1476
Pharmacokinetics of saquinavir ...... te in HIV-1-infected subjects.
@en
P2093
Andrew Hill
Anton Pozniak
Brian Gazzard
David Back
Giovanni Di Perri
Graeme Moyle
Jaqui Tomkins
Mark Nelson
Marta Boffito
Meredith Stainsby-Tron
P2860
P356
10.1111/J.1365-2125.2004.02240.X
P407
P577
2005-01-01T00:00:00Z